page_accueil_3_actus

Articles

• Vect-Horus announces agreement with Johnson&Johnson Innovation
  18 January 2019, by Jonathan NOWAK

  Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

• Meet Vect-Horus at OTS, Montreal, October 6-9, 2024
  2 October 2024, by Emmanuelle BETTENDORF

  Guillaume Jacquot and Emmanuelle Bettendorf will be representing Vect-Horus at the The Oligonucleotide Therapeutics Society (OTS) Annual Meeting, taking place in Montreal, Canada from October 6-9.
  This is the leading international meeting of renowned oligonucleotide scientists, bringing academia, research and business together, and we are excited to swap notes with other leading players in the field.
  👉 Click here for more on the meeting www.2024oligomeeting.com

• Signature of a Research Common Lab with the Institute for NeuroPhysiopathology (UMR7051 CNRS-AMU)
  28 January 2019, by Jonathan NOWAK

  Since its incorporation in 2005 VECT-HORUS is a leading partner of the French academic institutions CNRS and Aix-Marseille University. Indeed, the company as a spin-off of the NICN (UMR7259 CNRS-AMU) now Institute for NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, develops inventions and technologies derived from the “BBB and Neuroinflammation Team”. VECT-HORUS has established a long-term highly efficient collaboration with this (…)

• TIDES Europe: Oligonucleotide & Peptide Therapeutics in AMSTERDAM
  31 October 2019, by Elodie DORMES

  Dr Guillaume JACQUOT will present "Targeted Drug Delivery to the CNS and Peripheral Tissues Using the VECTrans® Innovative Technology" during the TIDES Europe, 12-15 November 2019.

• How blood–brain barrier technology is unleashing CNS therapies
  18 March, by Emmanuelle BETTENDORF

  We are proud to be featured in Nature, in an article exploring how we are enabling targeted drug delivery across the blood–brain barrier.
  This article highlights the potential of our VECTrans platform, which has the potential to transform the treatment of neurodegenerative disorders. The article goes into the science and data behind our approach as well as our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, Inc.
  Click below for the full article.
  👉 (…)

• Vect-Horus enters into Collaboration and License Agreement with ONO Pharmaceutical Co., Ltd.
  26 March 2019, by Jonathan NOWAK

  Vect-Horus S.A.S. announced today the signing of a collaboration and license agreement with Ono Pharmaceutical Co., Ltd., focused on the development of novel molecules targeting neurodegenerative diseases

• Vect-Horus Strengthens Board of Directors with Appointment of Jean-Christophe Dantonel as New Member
  14 November 2024, by Emmanuelle BETTENDORF

  We’re pleased to welcome Jean-Christophe Dantonel as a new member of the Vect-Horus Board of Directors!
  Dr. Dantonel brings over two decades of profound expertise in biological sciences, project management, and clinical research to his new role.
  “He brings key skills to our company at an important stage of its development, with a combination of clinical research and business experience which will be invaluable as we innovate to develop vectors that facilitate targeting and delivery of (…)

• AD/PD 2019​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in LISBON
  28 January 2019, by Jonathan NOWAK

  Marion DAVID and Romy COHEN will present the “Development of vectors that cross the blood brain barrier to enhance CNS drug delivery in neurodegenerative diseases” in session A: β-Amyloid Diseases poster n°ADPD9-1832

• Vect-Horus has been honored with a prestigious European Enterprise Award
  18 March, by Emmanuelle BETTENDORF

  We are thrilled to announce that Vect-Horus has been honored with a prestigious European Enterprise Award by EU Business News! Vect-Horus is cited as one of the Pharma & Biotech Innovators of the Year 2024 ».
  These awards recognize outstanding businesses thriving across Europe. This recognition highlights our ongoing commitment to innovation in biotechnology, particularly our efforts to revolutionize drug delivery using our unique VECTrans® technology.
  A heartfelt thank you to our (…)

• Vect-Horus announces Collaboration and Option Agreement with ASTELLAS Pharma
  4 June 2019, by Jonathan NOWAK

  Vect-Horus announced today the signing of the Research Collaboration and Option Agreement (the “Agreement”) with Astellas Pharma Inc., a Japan based pharmaceutical company (“Astellas”). Vect-Horus will use its proprietary technology VECTrans® to transport Astellas’ antibody to the brain for the treatment of CNS diseases.